Award
National Cancer Institute 2R44CA278293-04
Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas
Recipient
MYOSIN THERAPEUTICS INC.
Award Amount
$2,245,802.00
Ceiling
$2,245,802.00
Awarded
August 07, 2025
Identifier
2R44CA278293-04
NIH awarded a Phase 0/I clinical trial project for MT-125 monotherapy in recurrent high-grade gliomas with a focus on dose escalation, drug distribution, and preliminary efficacy.
Description
This NIH SBIR Phase IIB Bridge application aims to perform a Phase 0/1b clinical trial of MT-125 for glioblastoma, focusing on dose determination, drug distribution, and preliminary efficacy data. The project builds on prior research and has received Orphan Drug Designation from the FDA.